Janux Therapeutics, Inc. (JANX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 1.13B USD. 52-week range 12.12 to 35.34 USD. Data as of 2026-10-09.
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr), Tumor Activated Immunomodulator (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms technology to treat patients with cancer. The company's clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate ...